登录

Coronary Medical Devices Company HS Medical Raises ¥40M in Series Pre-A Round

Mailman 2020-01-21 17:28

恒升医疗
企业数据由 动脉橙 提供支持
心血管介入器械研发、生产、销售商 | A轮 | 运营中
中国-北京
2021-01-07
融资金额:RMB¥3亿
招银国际
查看

According to PEdaily.cn, Beijing Hengsheng Medical Group ("HS Medical"), a manufacturer of coronary medical devices, has completed its ¥40 million (US$5.83 million) series Pre-A round of financing, with participation from Changzhou West Taihu Lake Health Investment Company, the industry investment fund under the management of Changzhou West Taihu Lake Government. Proceeds of this funding will be used for product production, research and development, and clinical trials.


HS Medical focuses on production, R&D, sales and investment in the field of interventional medicine. At present, the investment of high-tech medical products factories and supporting facilities projects by the company is up to 350 million yuan, which are located in the Shunyi Development Zone in Beijing and cover an area of about 25 acres.


At present, HS Medical has a complete set of production lines for drug-eluting stents, balloon catheters and accessories. The company has been certified as a national high-tech enterprise with more than 30 patents (including applications), 4 European CE certificates and 9 NMPA (National Medical Products Administration) registration certificates, with a total R&D investment of more than 500 million yuan.


HS Medical has developed various balloon dilatation catheters, especially drug-coated balloon dilatation catheters. The drug-eluting balloon, which occupies an important position in the medical products of HS Medical, using the proprietary technology of "self-perfusion", has entered the late stage of its clinical trial, and is expected to complete the clinical trial and apply for registration in the first half of 2020, and be ready for market sale in 2021.


Nowadays, the imported products in the pharmaceutical balloon market occupy a large share in China, with a low level of localization and a large space for import substitution. That's to say, HS Medical still has a number of opportunities in the market.

相关赛道 心血管耗材
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。
推荐阅读

120多名医生参加了关于介入骨科和非手术治疗进展的会议

Medgate Today 2024-07-13 20:52

北京大学第三医院4个牵头项目荣获2023年北京医学科技奖

北京大学医学部 2024-07-13 20:23

与NeoRAS野生型转移性癌症相关的临床特征——SCRUM-Japan GOZILA亚研究

Nature 2024-07-13 19:13

Mailman

共发表文章3245篇

最近内容
查看更多
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

相关公司
查看更多

恒升医疗

心血管介入器械研发、生产、销售商

立即沟通

西太湖健康投资

健康产业项目基金投资公司

立即沟通
产业链接
查看更多